
As reproductive rights diminish in other states since the fall of Roe, New York has been a safe harbor. Much of the credit is due to Gov. Hochul.
She signed shield laws protecting New York providers who care for patients in other states. She ensured that New York stockpiled abortion medication and invested in providers so care would never be interrupted. When a Louisiana prosecutor indicted a New York doctor and sought her extradition, the governor refused. She then signed a law protecting prescribers’ identities so other doctors wouldn’t be targeted the same way.
Now she has a chance to write the next chapter. A bill to safeguard access to mifepristone (S.8544/A.9217), sponsored by state Sen. Michelle Hinchey and Assemblymember Amy Paulin, has passed the Legislature. It builds directly on the foundation the governor has laid.
The bill makes clear that prescribing, dispensing or taking mifepristone, or any certified medication abortion drug, stays legal in New York even if federal approval or rules change. It also helps protect New York doctors, nurse practitioners, midwives and pharmacists from prosecution and professional discipline for providing this safe, long-established care.
Mifepristone has been FDA-approved since 2000, has more than two decades of safety data behind it and is safely used worldwide. In the U.S., mifepristone is prescribed in a majority of abortions nationwide and is key for miscarriage management as well. Yet federal officials have announced a new review of the medication by the FDA. The review is an unwarranted and politically motivated attack on the well-established science behind mifepristone’s safety.
Abortion foes are simultaneously using litigation to try to limit access to medication abortion. This spring, a federal appeals court ruled in favor of Louisiana’s attempt to restore a medically unnecessary requirement that mifepristone only be dispensed in person. The law would have limited access to the medication nationwide, including for New Yorkers who rely on telemedicine to access reproductive health care. Fortunately the Supreme Court paused that order but the case continues in federal court in Louisiana.
This New York bill is about protecting the health care needs of New Yorkers. Mifepristone is not only essential for abortion but is a standard treatment for pregnancy loss. Research published in JAMA this year found that in states with abortion bans, patients managing a miscarriage were more likely to receive a less effective regimen without mifepristone. No New Yorker going through a pregnancy loss should be denied the best treatment available because federal officials caved to anti-abortion politics.
The bill will help make sure that patients in the North Country, the Southern Tier and other areas far from a clinic can continue to depend on telehealth. Working New Yorkers can’t always take days off for in-person visits. Childcare commitments can make it challenging or impossible for many women to travel far for necessary medical care. Telehealth puts access to care within reach. New Yorkers shouldn’t lose access to care because of a federal court ruling or regulatory notice that plays politics with our health.
Finally, the bill protects the health care workers we count on. Clinicians should be able to follow the science with confidence, and not need to consult a lawyer before writing a prescription.
With Hochul’s deep commitment to protecting women’s health and rights, New York has led the nation on preserving reproductive freedom. This bill keeps us in front and should be signed into law now. It makes sure the state’s promise holds, whatever happens in Washington in the weeks and months to come.
Kay is the founder and CEO of Reproductive Futures.